Literature DB >> 16275362

Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma.

Kimberly Mascia1, Tmirah Haselkorn, Yamo M Deniz, Dave P Miller, Eugene R Bleecker, Larry Borish.   

Abstract

BACKGROUND: Patients with aspirin sensitivity experience hyperplastic sinusitis and nasal polyposis. We speculated that similar mechanisms could be acting in the lower airway and that these individuals would demonstrate more severe asthma and irreversible loss of lung function.
OBJECTIVE: We sought to investigate the role of aspirin-exacerbated respiratory disease (AERD) as a risk factor for the development of irreversible airway obstruction.
METHODS: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study is a multicenter observational study of subjects with severe or difficult-to-treat asthma. Data were compared between subjects who reported asthma exacerbation after aspirin ingestion and those who did not. The primary measure of bronchodilator-resistant obstruction (possible remodeling) was the maximally achieved postbronchodilator spirometry averaged over the 3-year duration of the study.
RESULTS: Adult subjects (>/=18 years) with AERD (n = 459) were compared with subjects with non-aspirin-sensitive asthma (n = 2848). Subjects with AERD had significantly lower mean postbronchodilator percent predicted FEV(1) compared with subjects with non-aspirin-sensitive asthma (75.3% vs 79.9%, P < .001). Differences in spirometry between the 2 cohorts persisted after controlling for potential confounding variables. In addition, subjects with AERD were more likely to have severe asthma by means of physician assessment (66% vs 49%, P < .001), to have been intubated (20% vs 11%, P < .001), to have a steroid burst in the previous 3 months (56% vs 46%, P < .001), and to have required high-dose inhaled corticosteroids (34% vs 26%, P < .001).
CONCLUSIONS: These data suggest that aspirin sensitivity is associated with increased asthma severity and possible remodeling of both the upper and lower airways.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16275362     DOI: 10.1016/j.jaci.2005.08.035

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  47 in total

1.  ADAM33 polymorphisms are associated with aspirin-intolerant asthma in the Japanese population.

Authors:  Takuro Sakagami; Nobuyoshi Jinnai; Toshiaki Nakajima; Takashi Sekigawa; Takashi Hasegawa; Eiichi Suzuki; Ituro Inoue; Fumitake Gejyo
Journal:  J Hum Genet       Date:  2006-10-24       Impact factor: 3.172

2.  Development of a genetic marker set to diagnose aspirin-exacerbated respiratory disease in a genome-wide association study.

Authors:  H S Chang; S W Shin; T H Lee; D J Bae; J S Park; Y H Kim; S T Uh; B W Choi; M K Kim; I S Choi; B L Park; H D Shin; C S Park
Journal:  Pharmacogenomics J       Date:  2015-02-24       Impact factor: 3.550

3.  Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.

Authors:  John W Steinke; Lixia Liu; Phillip Huyett; Julie Negri; Spencer C Payne; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2013-06-24       Impact factor: 10.793

Review 4.  Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.

Authors:  Whitney Stevens; Kathleen Buchheit; Katherine N Cahill
Journal:  Curr Allergy Asthma Rep       Date:  2015-12       Impact factor: 4.806

Review 5.  Refractory asthma - An old disorder: Novel approaches for effective control.

Authors:  B N B M Prasad
Journal:  Med J Armed Forces India       Date:  2016-06-24

Review 6.  Chronic rhinosinusitis phenotypes.

Authors:  John W Steinke; Larry Borish
Journal:  Ann Allergy Asthma Immunol       Date:  2016-09       Impact factor: 6.347

7.  Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.

Authors:  Whitney W Stevens; Anju T Peters; Annemarie G Hirsch; Cara M Nordberg; Brian S Schwartz; Dione G Mercer; Mahboobeh Mahdavinia; Leslie C Grammer; Kathryn E Hulse; Robert C Kern; Pedro Avila; Robert P Schleimer
Journal:  J Allergy Clin Immunol Pract       Date:  2017-03-09

8.  Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics.

Authors:  Jong Sook Park; An Soo Jang; Sung Woo Park; Young Mok Lee; Soo Taek Uh; Yong Hoon Kim; Ji Yean Cha; Se Min Park; Choon-Sik Park
Journal:  Allergy Asthma Immunol Res       Date:  2009-12-30       Impact factor: 5.764

Review 9.  Ibuprofen: pharmacology, efficacy and safety.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2009-11-21       Impact factor: 4.473

Review 10.  Update on recent advances in the management of aspirin exacerbated respiratory disease.

Authors:  Nami Shrestha Palikhe; Joo-Hee Kim; Hae-Sim Park
Journal:  Yonsei Med J       Date:  2009-12-18       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.